Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 2 |
| GPCRs in Drug Discovery Introduction | 12 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| GPCRs in Drug Discovery Overview | 13 | 13 |
| Introduction | 13 | 1 |
| GPCR in the Human Genome | 14 | 1 |
| Introduction | 14 | 1 |
| The Traditional Classification System | 14 | 1 |
| The GRAFS Classification System | 15 | 1 |
| The Glutamate Receptor Family | 15 | 1 |
| The Rhodopsin Receptor Family | 16 | 1 |
| The Adhesion Family | 16 | 1 |
| The Frizzled/Taste2 Receptor Family | 16 | 1 |
| The Secretin Family | 16 | 1 |
| Structure of GPCRs | 17 | 1 |
| General Structure | 17 | 1 |
| Importance of the 7TM | 17 | 1 |
| Different Structures of the TM | 17 | 1 |
| TM Loop Formation | 17 | 1 |
| Structures of the TM Core and Disulphide Bonds | 17 | 1 |
| Structure of G-proteins | 18 | 1 |
| Coupling to G-proteins | 19 | 1 |
| Introduction | 19 | 1 |
| The Signal Transduction Pathways Involving GPCR | 19 | 1 |
| The cAMP Signal Pathway | 19 | 2 |
| The Phosphatidylinositol Signal Pathway | 21 | 1 |
| The G12/13 Coupled Receptors and RhoGEF Proteins | 21 | 1 |
| Second Messengers in the GPCR System | 22 | 1 |
| Introduction to Second Messengers | 22 | 1 |
| Cyclic Adenosine Monophosphate (cAMP) | 22 | 1 |
| Cyclic Guanosine Monophosphate (cGMP) | 23 | 1 |
| Diacylglycerol (DAG) | 23 | 1 |
| Inositol 1, 4, 5-triphosphate (IP3) | 24 | 1 |
| Calcium Ions (Ca2+ ) | 24 | 1 |
| Post-Translational Modifications | 25 | 1 |
| Glycosylation, Palmitoylation and Phosphorylation | 25 | 1 |
| GPCR Desensitization | 25 | 1 |
| GPCRs in Drug Discovery Novel Research Methods in GPCR Drug Discovery | 26 | 10 |
| Introduction | 26 | 1 |
| Structure-Based Research in GPCR | 26 | 1 |
| Introduction | 26 | 1 |
| New Avenues | 26 | 1 |
| Computational Modeling | 26 | 1 |
| X-Ray Crystallography | 26 | 1 |
| Alternative Biophysical Approaches | 27 | 1 |
| Case Studies | 27 | 1 |
| The Scripps Research Institute | 27 | 1 |
| Receptos Inc. | 27 | 1 |
| Fragment-Based Drug Discovery | 28 | 1 |
| Introduction | 28 | 1 |
| New Avenues | 28 | 1 |
| Case Study | 28 | 1 |
| Heptares Therapeutics | 28 | 1 |
| Ligand-Induced Selective Signaling (LiSS) | 28 | 1 |
| Introduction | 28 | 1 |
| New Avenues | 29 | 1 |
| Studies in Gonadotropin-Releasing Hormone (GnRH) | 29 | 1 |
| Biased Ligands | 29 | 1 |
| Case Study | 29 | 1 |
| Trevena Inc. | 29 | 1 |
| Allosterism and GPCRs | 29 | 1 |
| Introduction | 29 | 1 |
| New Avenues | 30 | 1 |
| Select Current Allosteric Modulators in Research | 30 | 1 |
| Allosteric Modulators of GPCR G Protein Coupling: Pepducins | 30 | 1 |
| Bitopic or Dualsteric Ligands | 30 | 1 |
| Collateral Efficacy and Permissive Antagonism | 31 | 1 |
| Case Studies | 31 | 1 |
| Addex Pharmaceuticals Ltd. | 31 | 1 |
| Anchor Therapeutics | 31 | 1 |
| Domain Therapeutics | 32 | 1 |
| GPCR Dimerization | 32 | 1 |
| Introduction | 32 | 1 |
| Need to Form Dimers | 32 | 1 |
| G Protein Activation Facilitation | 32 | 1 |
| Control of Cell Surface Delivery | 32 | 1 |
| New Avenues | 32 | 1 |
| Currently Employed Biochemical Techniques: Resonance Energy Transfer (RET) | 32 | 1 |
| PathHunter GPCR Dimerization System | 32 | 1 |
| Tag-lite Technology | 33 | 1 |
| Case Studies | 33 | 1 |
| DiscoveRx | 33 | 1 |
| Cisbio Bioassays | 33 | 1 |
| GPCR Oligomerization | 34 | 1 |
| Introduction | 34 | 1 |
| Classification of Oligomers | 34 | 1 |
| New Avenues | 35 | 1 |
| Changes in Ligand Recognition | 35 | 1 |
| Influence on G Protein Coupling | 35 | 1 |
| Transactivation | 35 | 1 |
| Case Studies | 35 | 1 |
| Cara Therapeutics | 35 | 1 |
| Dimerix Bioscience | 35 | 1 |
| GPCRs in Drug Discovery Orphan GPCRs | 36 | 6 |
| Introduction | 36 | 1 |
| Orphan GPCRs in the GRAFS Classification System | 36 | 1 |
| Orphan GPCRs in the Traditional Classification System | 37 | 1 |
| Current Methods Used in De-orphanization | 38 | 1 |
| Introduction | 38 | 1 |
| Reverse Pharmacology | 39 | 1 |
| Orphan Receptor Strategy | 40 | 1 |
| Phylogenetic Analysis and Chemogenomics | 40 | 1 |
| Functional Assays for De-orphanization | 40 | 1 |
| Introduction | 40 | 1 |
| G protein-dependent Assays | 40 | 1 |
| Recent G protein-independent Assays | 41 | 1 |
| Extracellular-Regulated Kinase (ERK) Activation Cell-based Assay | 41 | 1 |
| GPCR Internalization | 41 | 1 |
| GPCRs in Drug Discovery Pipeline Analysis by Therapeutic Class | 42 | 43 |
| Central Nervous System | 46 | 1 |
| Introduction | 46 | 1 |
| Pipeline Profile | 46 | 1 |
| Major Indications | 47 | 5 |
| Oncology | 52 | 1 |
| Introduction | 52 | 1 |
| Pipeline Profile | 52 | 1 |
| Major Indications | 53 | 3 |
| Cardiovascular System | 56 | 1 |
| Introduction | 56 | 1 |
| Pipeline Profile | 56 | 1 |
| Major Indications | 57 | 3 |
| Metabolic Disorders | 60 | 1 |
| Introduction | 60 | 1 |
| Pipeline Profile | 60 | 1 |
| Major Indications | 61 | 3 |
| Gastrointestinal Disorders | 64 | 1 |
| Introduction | 64 | 1 |
| Pipeline Profile | 64 | 1 |
| Major Indications | 65 | 2 |
| Respiratory Diseases | 67 | 1 |
| Introduction | 67 | 1 |
| Pipeline Profile | 67 | 1 |
| Major Indications | 68 | 3 |
| Immunology | 71 | 1 |
| Introduction | 71 | 1 |
| Pipeline Profile | 71 | 1 |
| Major Indications | 72 | 2 |
| Women s Health | 74 | 1 |
| Introduction | 74 | 1 |
| Pipeline Profile | 74 | 1 |
| Major Indications | 75 | 3 |
| Ophthalmology | 78 | 1 |
| Introduction | 78 | 1 |
| Pipeline Profile | 78 | 1 |
| Major Indications | 79 | 3 |
| Genito-Urinary System and Sex Hormones | 82 | 1 |
| Introduction | 82 | 1 |
| Pipeline Profile | 82 | 1 |
| Major Indications | 83 | 2 |
| GPRCs in Drug Discovery Pipeline Analysis by Indications | 85 | 33 |
| Diabetes | 88 | 1 |
| Introduction | 88 | 1 |
| Pipeline Profile | 88 | 1 |
| Analysis of Major Targets | 89 | 2 |
| Parkinson s Disease | 91 | 1 |
| Introduction | 91 | 1 |
| Pipeline Profile | 91 | 1 |
| Analysis of Major Targets | 92 | 2 |
| Pain | 94 | 1 |
| Introduction | 94 | 1 |
| Pipeline Profile | 94 | 1 |
| Analysis of Major Targets | 95 | 2 |
| Schizophrenia | 97 | 1 |
| Introduction | 97 | 1 |
| Pipeline Profile | 97 | 1 |
| Analysis of Major Targets | 98 | 2 |
| Obesity | 100 | 1 |
| Introduction | 100 | 1 |
| Pipeline Profile | 100 | 1 |
| Analysis of Major Targets | 101 | 2 |
| Hypertension | 103 | 1 |
| Introduction | 103 | 1 |
| Pipeline Profile | 103 | 1 |
| Analysis of Major Targets | 104 | 2 |
| Asthma | 106 | 1 |
| Introduction | 106 | 1 |
| Pipeline Profile | 106 | 1 |
| Analysis of Major Targets | 107 | 2 |
| Prostate Cancer | 109 | 1 |
| Introduction | 109 | 1 |
| Pipeline Profile | 109 | 1 |
| Analysis of Major Targets | 110 | 2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 112 | 1 |
| Introduction | 112 | 1 |
| Pipeline Profile | 112 | 1 |
| Analysis of Major Targets | 113 | 2 |
| Glaucoma | 115 | 1 |
| Introduction | 115 | 1 |
| Pipeline Profile | 115 | 1 |
| Analysis of Top Targets | 116 | 2 |
| GPCRs in Drug Discovery Competitive Landscape | 118 | 16 |
| GPCRs in Drug Discovery Major Companies With GPCR Platform Technology | 118 | 1 |
| Heptares Therapeutics Ltd. | 118 | 1 |
| Company Overview | 118 | 1 |
| Receptos Inc. | 118 | 1 |
| Company Overview | 118 | 1 |
| 7TM Pharma A/S | 119 | 1 |
| Company Overview | 119 | 1 |
| Dimerix Biosciences Pvt. Ltd. | 119 | 1 |
| Company Overview | 119 | 1 |
| Trevena, Inc. | 119 | 1 |
| Company Overview | 119 | 1 |
| Cara Therapeutics, Inc. | 120 | 1 |
| Company Overview | 120 | 1 |
| Addex Pharmaceuticals | 120 | 1 |
| Company Overview | 120 | 1 |
| Anchor Therapeutics | 121 | 1 |
| Company Overview | 121 | 1 |
| Domain Therapeutics | 121 | 1 |
| Company Overview | 121 | 1 |
| Euroscreen S.A. | 122 | 1 |
| Company Overview | 122 | 1 |
| Omeros Corporation | 122 | 1 |
| Company Overview | 122 | 1 |
| Arena Pharmaceuticals | 123 | 1 |
| Company Overview | 123 | 1 |
| Compugen, Ltd. | 123 | 1 |
| Company Overview | 123 | 1 |
| Tranzyme Pharma, Inc. | 124 | 1 |
| Company Overview | 124 | 1 |
| Oxagen Limited | 125 | 1 |
| Company Overview | 125 | 1 |
| Prosarix Ltd. | 125 | 1 |
| Company Overview | 125 | 1 |
| Acadia Pharmaceuticals Inc. | 126 | 1 |
| Company Overview | 126 | 1 |
| Actelion Ltd. | 127 | 1 |
| Company Overview | 127 | 1 |
| AcurePharma AB | 127 | 1 |
| Company Overview | 127 | 1 |
| DiscoveRx | 127 | 1 |
| Company Overview | 127 | 1 |
| GPCRs in Drug Discovery Top 5 Companies as per Number of Molecules in NDA Filed and in Phase III | 128 | 1 |
| Merck &Co., Inc. | 128 | 1 |
| Company Overview | 128 | 2 |
| Novartis AG | 130 | 1 |
| Company Overview | 130 | 1 |
| Pfizer Inc. | 131 | 1 |
| Company Overview | 131 | 1 |
| Eli Lilly and Company | 132 | 1 |
| Company Overview | 132 | 1 |
| Johnson and Johnson | 133 | 1 |
| Company Overview | 133 | 1 |
| GPCRs in Drug Discovery Strategic Consolidations | 134 | 5 |
| AstraZeneca Enters Into Co-Development Agreement With Heptares | 134 | 1 |
| Heptares Therapeutics Enters Into Option Licensing Agreement With Shire For Adenosine A2A | 134 | 1 |
| Dimerix Bioscience Enters Into Research Agreement With Takeda Cambridge | 135 | 1 |
| Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharmaceutical Company Ltd. | 135 | 1 |